FRAT regulator of Wnt signaling pathway 1Genealiases: []
Q-omics provides the consensus-scored FRAT1 profile across patient tissues and cancer cell-line models. FRAT1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FRAT1 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, FRAT1 RNA expression shows 19,111 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where FRAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRAT1 survival associations across molecular data types. FRAT1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRAT1 RNA expression–survival associations across cancer types. High FRAT1 expression shows favorable associations in HNSC, SCLC, UCEC, CESC, BRCA and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FRAT1 RNA expression.
This table summarizes FRAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FRAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRAT1 shows lower tumor expression in COAD, LUSC, LUAD and READ and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher FRAT1 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with FRAT1 in patient tissues and cancer cell lines. In patient samples, FRAT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FRAT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
